CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos
While at first sight, the body of aficamten data in obstructive hypertrophic cardiomyopathy (oHCM) may appear slightly ahead of Camzyos...
top of page
Recent Research
- Feb 5
MRK: One big hit amongst smaller approvable assets
MRK: We examine in detail, the prospects of five median term Merck pipeline assets, over the next 6 years and find that there are good...
- Nov 20, 2023
BMY/JNJ/BAYN: Bayer AF failure does not reduce chances for Factor XI in stroke
Bayer announced Monday that its Factor XIa phase III trial of asundexian to prevent strokes in high risk patients with atrial...
- Oct 31, 2023
AZN/GILD/Daiichi: ADC's face stiff hurdles in 1st line lung cancer
AZN/GILD/Daiichi: Market expectations are running high for ADC’s toxic payload in NSCLC We undertake a detailed analysis the current...
- Sep 18, 2023
JNJ/PTGX: JNJ2113: Oral dosing faces hurdles of new rival classes in psoriasis & Ulcerative Colitis
The injectable IL23 class has been successful in treating a wide variety of inflammatory conditions such as psoriasis and inflammatory...
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page